
	Where results make sense

Topic: Abciximab

Related Topics

Antiplatelet drug

Phosphodiesterase inhibitor

Tape gag

Aspirin

Simple English

Thomas Boggs

Trigon

Freckle

In the News (Thu 17 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Abciximab - Wikipedia, the free encyclopedia
		Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.
		Abciximab is indicated for use in individuals undergoing percutaneous coronary intervention (angioplasty with or without stent placement).
		Abciximab has a plasma half life of about ten minutes, with a second phase half life of about 30 minutes.
	en.wikipedia.org /wiki/Abciximab (435 words)

	ABCIXIMAB Drug Information ABCIXIMAB
		The heparin infusion was maintained during the Abciximab infusion and was adjusted to achieve an ACT of 300 seconds or an APTT of 70 seconds during the PCI.
		Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications.
		The incidence of intracranial hemorrhage was 3/3023 for placebo patients and 7/4680 for Abciximab patients.
	www.drugs.com /pdr/ABCIXIMAB.html (7217 words)

	Abciximab (Site not responding. Last check: 2007-10-25)
		Abciximab (c7E3) is a chimeric mouse-human monoclonal antibody directed against the GP IIb/IIIa receptor; its mechanism of action is thought to be steric hindrance of the receptor itself as opposed to direct binding to the RGD binding site of the receptor.
		Administration of abciximab has become widespread clinical practice during angioplasty in patients with a history of unstable angina, where there is visible thrombus or when an acute ischemic complication (dissection, closure) threatens the success of an elective angioplasty.
		Abciximab was the first GP IIb/IIIa receptor inhibitor and has the greatest wealth of clinical data.
	cvmed.stanford.edu /interventional/abcixima.htm (803 words)

	Diabetics Undergoing Angioplasty Benefit From Antiplatelet Drug Reopro (Abciximab)
		While patients treated with abciximab and angioplasty experienced sustained benefits after six months (51 percent reduction, compared with stents alone), these benefits were reduced at one year and are attributed to the lack of stent placement (9 percent reduction in death after one year, compared with patients treated with stent alone).
		Abciximab is currently being studied in combination with thrombolytic agents in order to find an optimal regimen that would assist with thrombolysis (the break-up of a blood clot).
		Abciximab - the first of a new class of drugs called glycoprotein (GP) IIb/IIIa inhibitors - reduces the complications associated with angioplasty, a common procedure used to treat patients with cardiovascular disease, by preventing the formation of blood clots that commonly intensify during the procedure.
	www.docguide.com /dg.nsf/PrintPrint/BFE0FBC91EC1A94885256974004BF88D (991 words)

	MedlinePlus Drug Information: Abciximab (Systemic) (Site not responding. Last check: 2007-10-25)
		Abciximab (ab-SIKS-ih-mab) is used to lessen the chance of heart attack in people who need percutaneous coronary intervention (PCI), a procedure to open blocked arteries of the heart.
		Abciximab is used with aspirin and heparin, which are other medicines used to keep your blood from clotting.
		Also, tell your doctor if you have received abciximab or heparin before and had a reaction to either of them called thrombocytopenia (a low platelet count in the blood), or if new blood clots formed while you were receiving the medicine.
	www.nlm.nih.gov /medlineplus/druginfo/uspdi/500417.html (1173 words)

	Hem/Onc Today: Differentiating between abciximab-induced thrombocytopenia and pseudothrombocytopenia
		Abciximab (ReoPro, Lilly) is a GP IIb/IIIa inhibitor approved by the FDA for use in patients undergoing PCI or patients with unstable angina not responding to conventional medical therapy when PCI is planned within 24 hours.
		Abciximab is a monoclonal antibody of a human-murine Fab fragment that has been shown to reduce the composite outcome of death, myocardial infarction (MI) or urgent target vessel revascularization as compared with placebo in patients undergoing PCI (EPIC, EPISTENT and EPILOG trials).
		The manufacturer of abciximab recommends checking a platelet count two to four hours after abciximab therapy is started and at 24 hours or prior to discharge, whichever is first.
	www.hemonctoday.com /200208/young.asp (1138 words)

	BioMed Central \| Full text \| Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the ...
		Abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) was added to the cultures for a period of 18 h.
		The effects of abciximab (0.0002, 0.002, 0.02, 0.2, 2.0, and 20.0 μg/ml) on migration of HCMSMC are shown in Figure 2 and Table 1.
		Due to the fact that a concentration of abciximab of 0,175 μg/mL is considered as maximal plasma level (MPL) after systemic infusion [18], the present data demonstrate that direct anti-migratory effects of abciximab may not contribute to the anti-restenotic effects described in experimental [33-39] and clinical [1,2,5-7] studies.
	www.biomedcentral.com /1471-2261/6/14 (4866 words)

	Abciximab
		Administration of abciximab is associated with increased frequency of major bleeding complications including retroperitoneal bleeding, spontaneous GI or GU bleeding, and bleeding at the arterial access site and in the following: patients weighing <75 kilograms, elderly patients (>65 years), history of previous GI disease, recent thrombolytic therapy.
		Abciximab may be used for 12-14 hours in individuals in whom a PCI is planned within the next 24 hours.
		Abciximab may also be used for 12-24 hours for individuals in whom a PCI is planned within the next 24 hours.
	www.musc.edu /pharmacyservices/Drugs/A/Abciximab.htm (1986 words)

	Superior In-Hospital and 30-Day Outcomes with Abciximab
		The benefit associated with the use of abciximab was consistent for all high-risk subgroups analyzed and especially pronounced among diabetic and female patients.
		For example, although abciximab binds more tightly to the GP IIb/IIIa receptor than eptifibatide, there is evidence for greater antiplatelet effect with eptifibatide, especially at the end of the infusion period and at pre-hospital discharge.
		Abciximab is shown to favorably alter the PCI-related inflammatory activation with the ability to reduce the rise in CRP (-32%), interleukin-6 (-76%) and tumor necrosis factor-a (-100%), as well as block neutrophil and monocyte activation compared with placebo.
	www.arabmedmag.com /issue-15-06-2005/cardiology/main04.htm (3878 words)

	[No title]
		In the high-risk patients in the EPIC trial, abciximab was best for those at the highest risk of ischemic complications - patients who were having a procedure to treat recent heart attack or unstable angina.
		Abciximab may also be good in those patients for whom the average cost of procedures is high, such as diabetics.
		Abciximab recipients were more likely to need bypass surgery within 6 months.
	www.cs.yale.edu /homes/reyzin/IWSpring2004/info/Is_Abciximab_worth_cost.txt (455 words)

	p030203b - Abciximab (ReoPro) or IIb/IIIa Class Drugs - Pulmonary Hemorrhage
		Abstract: Abciximab has a key role in the treatment of patients with acute coronary syndromes undergoing percutaneous coronary intervention; however, an increased risk of bleeding complications is well recognized.
		Abstract: STUDY OBJECTIVE: The use of abciximab, a chimeric monoclonal antibody Fab fragment specific for platelet glycoprotein IIb/IIIa receptors, is associated with improved outcome after angioplasty and stent placement.
		In the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial, the use of an abciximab bolus was associated with major bleeding complications in 11 percent of patients.
	www.emory.edu /WHSCL/grady/amreport/litsrch02/p030203b.html (788 words)

	Use of Abciximab for Mediation of Thromboembolic Complications of Endovascular Therapy -- Cloft et al. 22 (9): 1764 -- ...
		Abciximab is approved by the FDA for the prevention of thrombotic
		of heparin, abciximab, and t-PA in the presence of a ruptured
		Abciximab in acute ischemic stroke: a randomized, double-blind, placebo-controlled, dose-escalation study.
	www.ajnr.org /cgi/content/full/22/9/1764 (2002 words)

	Online, Description, Chemistry, Ingredients - Abciximab - RxList Monographs
		Abciximab, ReoPro, is the Fab fragment of the chimeric human-murine monoclonal antibody 7E3.
		Abciximab binds to the glycoprotein (GP) lIb/Ilia receptor of human platelets and inhibits platelet aggregation.
		Each single use vial contains 2 mg/mL of Abciximab in a buffered solution (pH 7.2) of 01 M sodium phosphate, 0.
	www.rxlist.com /cgi/generic2/abcixim.htm (169 words)

	Abciximab More Effective (Site not responding. Last check: 2007-10-25)
		The trial randomized 4,809 patients undergoing PCI with stenting to either abciximab or tirofiban.
		In terms of specific events, ACS patients treated with abciximab undergoing stent implantation had lower 30-day (5.8 percent vs. 8.5 percent, respectively) and six-month (7.1 percent vs. 9.6 percent, respectively) rates of MI than ACS patients with tirofiban.
		For ACS patients, 0.5 percent on abciximab and 1.1 percent on tirofiban experienced urgent TVR vs. 0.9 percent and 0.5 percent of non-ACS patients, respectively.
	www.cardiologyonline.com /journal_articles/Abciximab.htm (438 words)

	Abciximab Improves Safety Of Stenting Procedure For Heart Disease (Site not responding. Last check: 2007-10-25)
		The proportion was lower at 6.9 percent for the 796 patients given balloon angioplasty plus abciximab and lower still at 5.3 percent for those assigned stenting plus abciximab.
		The main outcomes that occurred less with the use of abciximab were death and large heart attack -- 7.8 percent in the placebo group, 4.7 percent for balloon angioplasty plus abciximab and three percent for stenting plus abciximab.
		Topol and colleagues said that use of abciximab substantially improves the safety of coronary-stenting procedures and that balloon angioplasty with abciximab is safer than stenting without abciximab.
	www.pslgroup.com /dg/8de36.htm (396 words)

	New Data Suggest Complementary Effects of Abciximab (ReoPro®) and Primary Stenting In Patients With Acute ... (Site not responding. Last check: 2007-10-25)
		The ADMIRAL (Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up) study is a double-blind, placebo controlled, multi-center trial of 300 AMI patients undertaken in 28 centers across France.
		Abciximab (ReoPro®) is marketed in Europe by Eli Lilly and Company and was developed by Centocor, Inc., Malvern, PA. For more information on ReoPro®, visit www.reopro.com.
		Abciximab – a unique multi-receptor antagonist – reduces complications associated with PTCA by preventing the formation of blood clots that commonly intensify during the procedure.
	www.jnj.com /news/jnj_news/20020307_1516.htm?pageTemplate=printer_friendly.jsp&contentPage=/news/news_content.jsp (1139 words)

	Evaluation of Local Abciximab Delivery from the Surface of a Polymer-coated Covered Stent: In Vivo Canine Studies -- ...
		and elution of abciximab from the surface of a polymer-coated
		because abciximab is an antibody to the vitronectin receptor
		and elution of abciximab from a polymer surface.
	www.jvir.org /cgi/content/full/12/4/487 (2885 words)

	Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets ...
		Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets -- Curtis et al.
		Abciximab was added to washed platelets suspended in PBS at a ratio of 0.7 µg abciximab per 1.6 × 10
		Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
	www.bloodjournal.org /cgi/content/full/99/6/2054 (4068 words)

	Intraarterially Administered Abciximab as an Adjuvant Thrombolytic Therapy: Report of Three Cases -- Kwon et al. 23 ...
		Angiograms show a thrombotic complication that occurred during embolization with Guglielmi detachable coils; this was successfully treated with intraarterial abciximab.
		Angiograms show a thrombotic complication that occurred during embolization with Guglielmi detachable coils; this was successfully treated with intraarterially administered abciximab.
		Abciximab, which is made by immunization of a mouse with human
	www.ajnr.org /cgi/content/full/23/3/447 (2969 words)

	News - Similar Early Outcomes With Eptifibatide and Abciximab Before Percutaneous Coronary Intervention: Presented at ...
		Stents were placed during 93.2% of procedures in the abciximab group and 88.6% of the eptifibatide group.
		Major adverse outcomes reported were all similar between abciximab and eptifibatide groups, including death (3.41% vs. 5.3%), recurrent MI (0% vs. 0.8%), total major adverse cardiovascular events (8% vs. 12.1%), stroke (0.6% vs. 0.08%) and repeat PCI (1.1% vs. 2.3%).
		The bleeding risk also appeared to be similar between abciximab and eptifibatide, with minor bleeds occurring in 10.2% and 12.9% and major bleeds 7.4% and 9.8%, respectively.
	www.docguide.com /news/content.nsf/news/852571020057CCF6852571700048F753 (559 words)

	Alveolar Hemorrhage as a Complication of Treatment With Abciximab -- Kalra et al. 120 (1): 126 -- Chest
		The infusion of abciximab (ReoPro; Eli Lilly; Indianapolis,
		Sundlof, DW, Rerkpattanapitat, P, Wongpraparut, N, et al (1999) Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
		Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization.
	www.chestjournal.org /cgi/content/full/120/1/126 (2169 words)

	Abciximab Bolus Injection Does Not Reduce Cerebral Ischemic Complications of Elective Carotid Artery Stenting: A ...
		Abciximab Bolus Injection Does Not Reduce Cerebral Ischemic Complications of Elective Carotid Artery Stenting: A Randomized Study -- Hofmann et al.
		Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages in ischemic complications of percutaneous coronary revascularization.
		Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
	stroke.ahajournals.org /cgi/content/full/33/3/725 (1756 words)

	ReoPro (Abciximab) and Scientific Publications Information
		Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT).
		Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels.
		Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.
	www.reopro.com /resources_tools/scientific_publications.jsp (451 words)

	ACUTE CARE, INC - abciximab
		NEW YORK (Reuters Health) - The ``super-aspirin'' abciximab is not beneficial for patients with acute coronary syndrome who are not undergoing treatment to clear blocked heart arteries, according to a new study.
		LONDON (Reuters Health) - After myocardial infarction, reperfusion therapy with the combination of reteplase and abciximab appears to be superior to reteplase alone, investigators from the GUSTO V trial report in a fast-track report published in the June 16th issue of The Lancet.
		He said that combined reteplase and abciximab therapy is ideal for patients with a moderate to large MI who are younger than 75, which includes the majority of patients who would normally get reperfusion therapy.
	www.acutecare.com /abciximab.htm (1012 words)

	Clinical Trial: Abciximab in Wake-Up Stroke
		The purpose of the prospective, randomized, double blind, placebo-controlled multicenter pilot study is to evaluate the effectiveness of abciximab on rescuing the hypoperfused brain tissue, as assessed by MRI, and the relative safety of abciximab in patients with wake-up stroke.
		Primary Outcomes: To investigate whether abciximab compared with placebo is able to save brain tissue as assessed by MRI performed prior to inclusion in the study and 5-7 days after stroke onset:; 1.
		A phase IIa placebo-controlled safety and pilot efficacy trial of abciximab in patients with acute ischemic stroke treated within 24 hours from symptoms onset found that abciximab caused no symptomatic intracranial hemorrhage and showed a trend toward a higher rate of patients with minimal residual disability1.
	clinicaltrials.gov /ct/show/NCT00167765 (1282 words)

	Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction: Results From the ...
		Cost-Effectiveness of Coronary Stenting and Abciximab for Patients With Acute Myocardial Infarction
		Abciximab (Centocor) was administered as a 0.25-mg/kg bolus,
		Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction.
	circ.ahajournals.org /cgi/content/full/108/23/2857 (3159 words)

	Abciximab (Systemic) - MayoClinic.com
		Studies on this medicine have been done only in adult patients, and there is no specific information comparing use of abciximab in children with use in other age groups.
		Bleeding problems may be especially likely to occur in elderly patients, who are usually more sensitive than younger adults tot the effects of abciximab.
		The presence of other medical problems may affect the use of abciximab.
	www.mayoclinic.com /health/drug-information/DR500417 (1187 words)

Try your search on: Qwika (all wikis)